Pulmonary arterial hypertension (PAH)
- Confirm PAH with specialist evaluation/RHC
- Initial combination therapy is common
- endothelin antagonist + PDE5 inhibitor
- Higher-risk disease → add prostacyclin pathway
- Riociguat replaces—not combines with—PDE5 drug
- Follow risk markers and escalate early
- Treat underlying connective-heart/lung disease
Use at a glance
- Confirm PAH with specialist evaluation/RHC
Treatment options
- Initial combination therapy is common
- endothelin antagonist + PDE5 inhibitor
Other treatment options
- Riociguat replaces—not combines with—PDE5 drug
- Treat underlying connective-heart/lung disease
Monitoring / follow-up
- Higher-risk disease → add prostacyclin pathway
- Follow risk markers and escalate early
Self-check
- What should be treated in Pulmonary arterial hypertension (PAH)?
underlying connective-heart/lung disease.
- What should be confirmed before treating Pulmonary arterial hypertension (PAH)?
PAH with specialist evaluation/RHC.
Drugs used for this (8)
All clinical uses · Open the interactive console ↗
